Healthcare Consolidation Broadens
GSK's $10.6 billion Nuvalent acquisition made targeted oncology a major portfolio priority. Later announcements from AbbVie and Merck connected that deal to a wider healthcare buying surge driven by pipeline replacement, laboratory tools, and patent-cliff pressure.